First Time Loading...

Immunoprecise Antibodies Ltd
XTSX:IPA

Watchlist Manager
Immunoprecise Antibodies Ltd Logo
Immunoprecise Antibodies Ltd
XTSX:IPA
Watchlist
Price: 6.5 CAD 0.78% Market Closed
Updated: May 10, 2024

Immunoprecise Antibodies Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Immunoprecise Antibodies Ltd
Income from Continuing Operations Peer Comparison

Comparables:
ABCL
ARCH
RP
IOT

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Immunoprecise Antibodies Ltd
XTSX:IPA
Income from Continuing Operations
-CA$7.3m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abcellera Biologics Inc
NASDAQ:ABCL
Income from Continuing Operations
-$146.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arch Biopartners Inc
XTSX:ARCH
Income from Continuing Operations
-CA$5.5m
CAGR 3-Years
14%
CAGR 5-Years
-10%
CAGR 10-Years
-39%
Replicel Life Sciences Inc
XTSX:RP
Income from Continuing Operations
-CA$69.3k
CAGR 3-Years
69%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Innovotech Inc
XTSX:IOT
Income from Continuing Operations
-CA$157.6k
CAGR 3-Years
N/A
CAGR 5-Years
-4%
CAGR 10-Years
15%

See Also

What is Immunoprecise Antibodies Ltd's Income from Continuing Operations?
Income from Continuing Operations
-7.3m CAD

Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Income from Continuing Operations amounts to -7.3m CAD.

What is Immunoprecise Antibodies Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-12%

Over the last year, the Income from Continuing Operations growth was -48%. The average annual Income from Continuing Operations growth rates for Immunoprecise Antibodies Ltd have been -12% over the past three years .